| 000 -LEADER |
|---|
| fixed length control field |
06444nam a22005055i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-1-59745-292-2 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20161121230840.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100301s2008 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781597452922 |
| -- |
978-1-59745-292-2 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-1-59745-292-2 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC254-282 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED062000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.994 |
| Edition number |
23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Jakowlew, Sonia B. |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Transforming Growth Factor-β in Cancer Therapy, Volume I |
| Medium |
[electronic resource] : |
| Remainder of title |
Basic and Clinical Biology / |
| Statement of responsibility, etc. |
by Sonia B. Jakowlew. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Totowa, NJ : |
| Name of producer, publisher, distributor, manufacturer |
Humana Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XXIV, 735 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Basic Concepts of TGF-? Signaling in Normal Physiology and Cancer Pathobiology -- Component Hardware for Transforming Growth Factor-? Signal Transduction: TGF-? Ligands, TGF-? Receptors, and Smads -- TGF-? Signaling in Homeostasis and Cancer -- TGF-? Availability: Latent TGF-? and Latent TGF-? Binding Proteins -- Biological Functions of Latent TGF-?-Binding Proteins and Activation of TGF-? -- Regulators of Smad2/3 Transcription and Phosphorylation -- Interaction of Smad4 and Embryonic Liver Fodrin-?-spectrin in Hyperplasia, Neoplasia, and Tumor Suppression -- Regulation of Smad Activity by Phosphorylation -- Nuclear Targeting of TGF-?-Activated Smads in Normal and Tumor Biology -- Ski, SnoN, and Akt as Negative Regulators of Smad Activity: Balancing Cell Death and Cell Survival -- Transforming Growth Factor-? in Cancer Therapy: Smurfs in TGF-? Signaling and Regulation of Bone Homeostasis and Cancer -- Involvement of km23 Dynein Light Chains in TGF ? Signaling -- TGF-? Signaling in Fibroblastic Cells and Oncogenesis -- Mechanisms of TGF-?-Induced Apoptosis in Cancer Cells -- Mechanisms of Cell Cycle Regulation by TGF-? Disabled in Cancer -- Transforming Growth Factor-? in Cancer Therapy -- TGF-? and Smad Signaling in Transcriptome Reprogramming During EMT -- Functional Interactions Between MMPs and TGF-? in Normal and Tumor Tissue -- Cooperation Between TGF-? and Wnt Pathway Components in Regulating Mesenchymal Stem Cell Function -- Interaction of Oncogenic Ras and TGF?1 Signaling in Cancer: Lessons From the Multistage Skin Carcinogenesis Model -- TGF-? Superfamily Members in Normal and Tumor Biology -- Proteomics Analysis of TGF? Superfamily Members -- Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers -- Activins, Inhibins, and Bone Morphogenetic Proteins as Modulators and Biomarkers of Prostate Cancer Progression -- Bone Morphogenic Proteins and Angiogenesis in Developing Tumors -- Histone Methyltransferase and Smad Interactions in BMP Signaling -- Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies -- Activins and Inhibins in Cancer Progression -- Bone Morphogenetic Proteins/Growth Differentiation Factors and Smad Activation in Ovarian Granulosa Cells and Carcinoma -- Regulation of the Transforming Growth Factor-? Superfamily by Betaglycan -- Uterine Sensitization Associated Gene-1: A Bone Morphogenetic Protein Antagonist with a Role in Kidney -- Role of Betaig-h3 Gene in Carcinogenesis -- Activins and the Liver -- Myostatin Signaling in Normal and Tumor Cells -- TGF-? in Inflammation and Fibrosis -- Triterpenoids, Vitamin D, and TGF-?/Smad Signaling in Inflammation and Cancer -- Thrombospondin-Dependent Activation of Latent TGF-? in Fibrosis and Disease -- TGF-? in Pulmonary Fibrosis -- The Role of TGF-? in Bleomycin Induced Pulmonary Fibrosis -- Smads in the Fibrotic Response: Findings in the Smad3 Knockout Mouse -- TGF-? Signaling in Renal Fibrosis and Inflammation: Gene Therapy Using Ultrasound-Microbubble-Mediated Inducible Smad7 -- Transforming Growth Factor-? Peptide Signaling in Pulmonary Development, Bronchopulmonary Dysplasia, Fibrosis, and Emphysema -- The Role of TGF-? in Radiation and Chemotherapy Induced Pulmonary Fibrosis: Inhibition of TGF-? as a Novel Therapeutic Strategy -- Negative Regulation of the TGF-? Family Signal Pathway by Inhibitory Smads and Their Involvement in Cancer and Fibrosis -- TGF-?-Related Antifibrotic Strategies in the Eye -- Transforming Growth Factor-? in Cutaneous Tissue Repair -- Topical Application of TGF-?1 Peptide Inhibitors for the Therapy of Skin Fibrosis -- Overexpressed Truncated TGF-? Type II Receptor Inhibits Fibrotic Behavior of Keloid Fibroblasts In Vitro and Experimental Scar Formation In Vivo. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Transforming Growth Factor-ß in Cancer Therapy, Volumes 1 and 2, provide a compendium of findings about the role of transforming growth factor-ß (TGF-ß) in cancer treatment and therapy. The first volume, Basic and Clinical Biology, is divided into three parts. Part I presents basic concepts of transforming growth factor-ß signaling in normal physiology and cancer pathobiology. Part II investigates transforming growth factor-ß superfamily members in normal and tumor biology. Part III details transforming growth factor-ß in inflammation and fibrosis. This volume’s companion, Cancer Treatment and Therapy, examines transforming growth factor-ß in several developing and advanced cancers and discusses methods of treatment and therapy. Together, Transforming Growth Factor-ß in Cancer Therapy, Volumes 1 and 2, provide researchers and clinicians with a comprehensive and cutting-edge reference for the findings about the role of transforming growth factor-ß in biology and cancer treatment. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer research. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cell biology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine & Public Health. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cell Biology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology/Toxicology. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9781588297143 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Cancer Drug Discovery and Development |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-59745-292-2 |
| 912 ## - |
|---|
| -- |
ZDB-2-SME |
